MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting

Phase 2

MyeloMATCHMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05564390

Conditions

Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm

Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia, Myelodysplasia-Related

Myelodysplastic Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Allogeneic Hematopoietic Stem Cell Transplantation

Azacitidine

Best Practice

Biopsy Procedure

Biospecimen Collection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-13. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-02-06.